Shearman P J, Longenecker B M
Int J Cancer. 1981 Mar 15;27(3):387-95. doi: 10.1002/ijc.2910270319.
Monoclonal antibodies were used to probe the cell surface of organ-selected metastatic variant cells. Previously we defined a liver metastasis-associated antigen (LMAA) by means of the reaction of a monoclonal antibody with a liver metastasis selected tumour variant cell line, MDCC-AL2. The monoclonal anti-LMAA antibodies specifically inhibit liver metastasis of AL2. There is a correlated, clonal variation in LMAA expression and liver metastasis in both the AL2 cell line and an overy-selected metastatic variant MDCC-AL3. The variation in liver metaatatic ability is thought to represent clonal progression of the tumour cell lines. The LMAA probably represents only one of the ways in which a tumour cell may give rise to a live metastasis. Two hypotheses are discussed utilizing the LMAA in a functional role in the specific trapping of metastatic tumour cells in the liver or the successful colonization of the liver by metastatic tumour cells.
单克隆抗体被用于探测器官选择性转移变异细胞的细胞表面。此前，我们通过一种单克隆抗体与一个肝脏转移选择肿瘤变异细胞系MDCC-AL2的反应，定义了一种肝脏转移相关抗原（LMAA）。单克隆抗LMAA抗体可特异性抑制AL2的肝脏转移。在AL2细胞系和一个卵巢选择的转移变异细胞系MDCC-AL3中，LMAA表达和肝脏转移存在相关的克隆变异。肝脏转移能力的变化被认为代表了肿瘤细胞系的克隆进展。LMAA可能只是肿瘤细胞产生肝转移的一种方式。利用LMAA在将转移性肿瘤细胞特异性捕获在肝脏中或转移性肿瘤细胞在肝脏中成功定植的功能作用，讨论了两种假说。
